KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (2016 - 2025)

Sarepta Therapeutics has reported Shares Outstanding over the past 16 years, most recently at $105.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 8.99% year-over-year to $105.6 million; the TTM value through Dec 2025 reached $105.6 million, up 8.99%, while the annual FY2025 figure was $105.6 million, 8.99% up from the prior year.
  • Shares Outstanding for Q4 2025 was $105.6 million at Sarepta Therapeutics, roughly flat from $105.4 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $105.6 million in Q4 2025 and troughed at $79748.0 in Q1 2021.
  • A 5-year average of $61.7 million and a median of $87.9 million in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: crashed 99.9% in 2021 and later surged 109663.75% in 2022.
  • Year by year, Shares Outstanding stood at $87127.0 in 2021, then soared by 100844.6% to $88.0 million in 2022, then increased by 6.57% to $93.7 million in 2023, then rose by 3.38% to $96.9 million in 2024, then rose by 8.99% to $105.6 million in 2025.
  • Business Quant data shows Shares Outstanding for SRPT at $105.6 million in Q4 2025, $104.8 million in Q3 2025, and $98.4 million in Q2 2025.